Febuxostat Teijin/Ipsen/TAP

Current Opinion in Investigational Drugs

Volumn 6, Issue 11, 2005, Pages 1168-1178

  Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

8 [3 METHOXY 4 (PHENYLSULFINYL)PHENYL]PYRAZOLO[1,5 A][1,3,5]TRIAZIN 4 OL; ALLOPURINOL; AN 260; ANTACID AGENT; COLCHICINE; DESIPRAMINE; FEBUXOSTAT; NAPROXEN; OXIPURINOL; PLACEBO; UNCLASSIFIED DRUG; URATE OXIDASE; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR; Y 700;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; GOUT; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IC 50; KIDNEY INJURY; LIVER DYSFUNCTION; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GOUT; HUMANS; PATENTS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; XANTHINE OXIDASE;

EID: 28244494585     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 172279 Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Komoriya K, Osada Y, Hasegawa M, Horiuchi H, Kondo S, Couch RC, Griffin TB EUR J PHARMACOL 1993 250 3 455-460
2. 172281 Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K EUR J PHARMACOL 1993 241 2-3 183-188
3. 343275 Drug development pipeline: TEI-6720 and TEI-6469. Teijin Ltd COMPANY COMMUNICATION 1999 October 13
4. 343974 Teijin licenses TMX-67, gout treatment, to TAP Holdings. PHARMA JAPAN 1999 1668 10
5. 365106 Hypouricemic activity of a novel xanthine oxidase/xanthine dehydrogenase (XOD/XDH) inhibitor, TEI-6720 in rats. Horiuchi H, Ota M, Kobasyashi M, Kaneko H, Kasahara Y, Nishimura S, Kondo S, Komoriya K JPN J PHARMACOL 2000 82 1 P-606
6. 379985 Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Horiuchi H, Ota M, Nishimura S, Kaneko H, Kasahara Y, Ohta T, Komoriya K LIFE SCI 2000 66 21 2051-2070
7. 379987 Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, Higashino K, Hada T PHARMACOLOGY 2000 60 1 34-40
8. 379988 Allopurinol increases ear swelling and mortality in a dinitrofluorobenzene-induced contact hypersensitivity mouse model. Horiuchi H, Ota M, Kitahara S, Ohta T, Kiyoki M, Komoriya K BIOL PHARM BULL 1999 22 8 810-815
9. 379989 A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Horiuchi H, Ota M, Kobayashi M, Kaneko H, Kasahara Y, Nishimura S, Kondo S, Komoriya K RES COMM MOL PATHOL PHARMACOL 1999 104 3 307-319
10. 379991 Nephrotoxic effects of allopurinol in dinitrofluorobenzenesensitized mice: Comparative studies on TEI-6720. Horiuchi H, Ota M, Kaneko H, Kasahara Y, Ohta T, Komoriya K RES COMM MOL PATHOL PHARMACOL 1999 104 3 293-305
11. 388243 BioPartnering - TAP Pharmaceuticals Inc. ANNU BIOPARTNERING EUROPE MEET 2000 8 October 16-17
12. 398274 Drug development pipeline - Abbott Laboratories. From a presentation by Miles D White CEO of Abbott at the Merrill Lynch Global Healthcare Conference, February 6-8, 2001. Abbott Laboratories. COMPANY WORLD WIDE WEB SITE 2001 February 08
13. 429705 Abbott Laboratories: Credit Suisse First Boston Health Care Conference. Abbott Laboratories COMPANY PRESENTATION 2001 November 14
14. 462792 Teijin aims at ¥200 billion drug sales via M&As, JV. PHARMA JPN 2002 1808 August 26
15. 470328 American College of Rheumatology - 66th Annual Scientific Meeting, New Orleans, LA, USA. Sylvester B IDDB MEETING REPORT 2002 October 25-29
16. 478775 Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. Joseph-Ridge N AM COLL RHEUMATOL 2002 October 25-29 Abs 289
17. 491208 Abbott Laboratories - 2003 R&D update. Abbott Laboratories COMPANY PRESENTATION 2003 May 29
18. 496132 Agreement between Teijin Limited and Ipsen for the development and the marketing of four Ipsen products in Japan and a new agent discovered by Teijin Limited in Europe. Teijin Ltd PRESS RELEASE 2003 July 07
19. 497926 An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T J BIOL CHEM 2003 278 3 1848-1855
20. 546527 EULAR 2004 - Annual European Rheumatology Congress, Berlin, Germany. Erlandsson Harris H IDDB MEETING REPORT 2004 June 9-12
21. 548190 Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Kamatani N, Fujimori S, Hada T, Hosoya T, Kato R, Matsuzawa Y, Ueda T ARTHRITIS RHEUM 2008 48 9 Suppl S530
22. 548192 Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase. Swan S, Khosravan R MMD, Wu JT, Palo WA, MacDonald PA, Vernillet L, Joseph RN ARTHRITIS RHEUM 2003 48 9 Suppl S529
23. 548193 Effect of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), on enzymes in purine and pyrimidine metabolism pathway. Zhao L, Takano Y, Horiuchi H ARTHRITIS RHEUM 2003 48 9 Suppl S351
24. 552291 Result of 1Q and Outlook for FY04. Teijin Ltd COMPANY PRESENTATION 2004 August 03
25. 552419 Consolidated Financial Results for the First Quarter of FY2004. Teijin Ltd PRESS RELEASE 2004 August 03
26. 565234 Data Presented at American College of Rheumatology Meeting on Febuxostat, an Investigational Therapy for Hyperuricemia Associated With Gout. TAP Pharmaceutical Products Inc PRESS RELEASE 2004 October 19
27. 565235 TAP's febuxostat superior to allopurinol for gout. TAP Pharmaceutical Products Inc PRESS RELEASE 2004 October 19
28. 565461 Febuxostat, a non-purine selective inhibitor of xanthine oxidase - effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety. Khosravan R, Mayer M, Grabowski B, Vernillet L, Wu JT, Joseph-Ridge N ARTHRITIS RHEUM 2004 50 Suppl 9 806/186
29. 565465 A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidase. Schumacher HR, Wortmann R, Becker MA, MacDonald P, Palo WA, Eustace D, Streit J, Joseph-Ridge N ARTHRITIS RHEUM 2004 50 Suppl 9 800/180
30. 565467 Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients. Becker MA, Schumacher R, Wortmann R, MacDonald P, Palo W, Joseph-Ridge N ARTHRITIS RHEUM 2004 50 Suppl 9 800/103
31. 576209 TAP files oral febuxostat NDA for gout. TAP Pharmaceutical Products Inc PRESS RELEASE 2004 December 15
32. 579485 TAP submits NDA for febuxostat for hyperuricemia in chronic gout. PHARMA JPN 2004 1924 7
33. 579816 Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2004 23 8-9 1119-1122
34. 579817 PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2004 23 8-9 1117-1118
35. 579818 Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2004 23 8-9 1111-1116
36. 590987 American Society of Clinical Pharmacology and Therapeutics - 2005 Annual Meeting, Orlando, FL, USA. Susman E, Susman R IDDB MEETING REPORT 2005 March 02-06
37. 592281 Teijin: Pharma, home health care sales up 2.1% to ¥73.7 billion. PHARMA JPN 2005 1932 21
38. 592289 Usefulness of new gout remedy TMX-67 reported: JSGNAM meeting. PHARMA JPN 2005 1932 26
39. 607074 Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA LIFE SCI 2005 76 16 1835-1847
40. 607075 Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Becker MA, Schumacher HRJ, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N ARTHRITIS RHEUM 2005 52 3 916-923
41. 607076 Recent advances in the management of gout and hyperuricemia. Wortmann RL CURR OPIN RHEUMATOL 2005 17 3 319-324
42. 607077 Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Mayer MD, Khosravan Reza VL, Wu JT, Joseph-Ridge N, Mulford DJ AM J THER 2005 12 1 22-34
43. 607078 A phase 3 study comparing the safety and efficacy of oral febuxostat and allopurinol in subjects with hyperuricemia and gout. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo W, Eustace D, Joseph RN ARTHRITIS RHEUM 2004 50 12 4103-4104
44. 607081 Y-700 (1-(3-cyano-4-(2,2-dimethylpropoxy)phenyl)-1H-pyrazole-4-carboxylic acid): A potent xanthine oxidoreductase inhibitor with hepatic excretion. Fukunari A, Okamoto K, Nishino T, Eger BT, Pai EF, Kamezawa M, Yamada I, Kato N J PHARMACOL EXP THER 2004 311 2 519-528
45. 607224 Ipsen: Dynamic growth confirmed in 2004. Ipsen PRESS RELEASE 2005 May 11
46. 612675 Ipsen website pipeline. Ipsen COMPANY WORLD WIDE WEB SITE 2005 July 18
47. 621011 A literature review of the epidemiology and treatment of acute gout. Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX CLIN THER 2003 25 6 1593-1617
48. 621073 Management of acute and chronic gouty arthritis: Present state-of-the-art. Schlesinger N DRUGS 2004 64 2399-2416
49. 621076 The metabolic syndrome. Eckel RH, Grundy SM, Zimmet PZ LANCET 2005 365 1415-1428
50. 621079 Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. Fang J, Alderman MH J AM MED ASSOC 2000 283 18 2404-2410
51. 621081 Gout and hyperuricemia. Wortmann RL CURR OPIN RHEUMATOL 2002 14 3 281-286
52. 622265 Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Wortmann R, Becker MA, Schumacher HR, MacDonald P, Palo WA, Joseph-Ridge N ARTHRITIS RHEUM 2004 50 Suppl 9 801/103
53. 622288 Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Becker MA, Schumacher R, Wortmann R, MacDonald P, Palo W, Joseph-Ridge N ARTHRITIS RHEUM 2004 50 Suppl 9 802/103
54. 622707 Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia. Kamatani N, Fujimori S, Hada T, Hosoya T, Matsuzawa Y, Ueda T, Yamanaka H, Kato R ARTHRITIS RHEUM 2004 50 Suppl 9 804/103
55. 623063 Prevention and treatment of the metabolic syndrome. Daskalopoulou SS, Mikhailidis DP, Elisaf M ANGIOLOGY 2004 55 6 589-612
56. 623111 The management of gout. Emmerson BT N ENGL J MED 1996 334 7 445-451
57. 623112 Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr J RHEUMATOL 2001 28 3 577-580
58. 623119 Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Becker MA RHEUM DIS CLIN NORTH AM 1988 14 2 377-394
59. 623353 Effects of age and gender on febuxostat pharmacokinetics. Pharmacodynamics, and safety in healthy subjects. Khosravan R, Kukulka M, Wu JT, Joseph-Ridge N Vernillet L CLIN PHARMACOL THER 2005 77 2 Suppl S P50
60. 623354 Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects. Khosravan R, Erdman K, Vernillet L, Wu J T, Joseph-Ridge N, Umeda S, Mulford D CLIN PHARMACOL THER 2005 77 2 Suppl S P43
61. 623355 Effect of food or antacid in febuxostat pharmacokinetics and pharmacodynamics in healthy subjects. Khosravan R, Grabowski V, Wu JT, Joseph Ridge N, Vernillet L CLIN PHARMACOL THER 2005 77 2 P50
62. 623356 A safety and efficacy clinical trial of a novel non-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout. Becker MA, Schumacher H Jr, Wortmann RL, Joseph Ridge N, Lademacher C ANN RHEUM DIS 2004 63 Suppl 1 OP0007
63. 623381 Recent advances in the epidemiology of gout. Saag KG, Mikuls TR CURR RHEUMATOL REP 2005 7 235-241
64. 623481 HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ et al PROC NATL ACAD SCI USA 2005 102 11 4134-4139
65. 626466 Abt: Stock down but lots of positive catalysts on TAP. Wise R, Bailey M BEAR STEARNS GROUP MORNING MEET NOTES 2004 September 20 1-3